ArticleAnnals of surgical oncology2026
Smooth Muscle Disruptive Feature Defines Molecular Subtyping, Risk Stratification, and Metastatic Potential in Prostate Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Leading Consortiums from the Ground Up: Leveraging Trainee Collaboration to Create Consensus Guidelines.Annals of surgical oncology · 2026Article
- New Consensus Statements for Peritoneal Surface Malignancy.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSmooth muscle (SM) invasion represents a critical feature of prostate cancer (PCa) progression and metastasis. This study aimed to develop a SM-based molecular score for progression and metastasis forecasting for PCa. PATIENTS AND
methodsA total of 952 patients with PCa with transcriptomic sequencing data and corresponding clinical information were included in this study to develop and validate a SM-related signature (SM score). SM-related molecular subtypes were identified on the basis of 35 smooth muscle-related gene sets using unsupervised clustering. Weighted gene coexpression network analysis (WGCNA) was employed to identify key SM-related genes. The SM score was subsequently developed using machine learning across, The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) training cohort and four independent external validation cohorts.
resultsUtilizing 35 gene sets related to SM function, we identified pronounced SM disruption in PCa compared with normal prostate tissues. Unsupervised consensus clustering stratified patients into two distinct molecular subtypes, which exhibited significant differences in prognosis and immune infiltration profiles. We subsequently developed a robust prognostic signature termed SM score, and multiomics analyses confirmed a strong association between the SM score and SM disruption. The SM score consistently demonstrated superior prognostic performance across all cohorts and showed potential as a biomarker for responsiveness to immunotherapy. Notably, SM score was significantly elevated in metastatic lesions compared with primary tumors and normal tissues and accurately predicted metastatic potential.
conclusionsSM disruption is associated with tumor progression in PCa. The SM score captures SM disruption and predicts PCa progression and metastasis potential, aiding personalized immunotherapy decisions.
Indexed as
Identifiers
41428021What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.